Edition:
United States

VIVUS Inc (VVUS.OQ)

VVUS.OQ on NASDAQ Stock Exchange Global Select Market

1.40USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$1.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
53,993
52-wk High
$1.84
52-wk Low
$0.92

VVUS.OQ

Chart for VVUS.OQ

About

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $146.78
Shares Outstanding(Mil.): 104.84
Dividend: --
Yield (%): --

Financials

  VVUS.OQ Industry Sector
P/E (TTM): -- 30.04 30.65
EPS (TTM): -0.44 -- --
ROI: -21.11 15.86 15.23
ROE: -- 16.96 16.56

BRIEF-Vivus reports Q3 net loss per share $0.09

* Qtrly total revenue $13.4 million versus $24.9 million Source text for Eikon: Further company coverage:

Nov 09 2016

BRIEF-Vivus and Metuchen Pharmaceuticals announce license agreement for commercial rights to Stendra

* VIVUS Inc says additionally, Metuchen will be responsible for royalties due to Mitsubishi Tanabe Pharma corporation based on net sales

Oct 03 2016

BRIEF-Vivus says extends return date of Stendra commercial rights

* Vivus inc says extends return date of stendra commercial rights

Aug 29 2016

BRIEF-Vivus posts qtrly rev $13.8 mln vs $23.0 mln last year

* Qtrly revenue $13.8 million versus $23.0 million Source text for Eikon: Further company coverage:

Aug 04 2016

BRIEF-Vivus says to extend return date of Stendra commercial rights

* Vivus Inc says to extend return date of Stendra commercial rights

Jun 30 2016

BRIEF-Vivus receives notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets

* Received notice from Hetero USA that it has filed with U.S. FDA ANDA for generic versions of all strengths of Stendra tablets

Jun 21 2016

Earnings vs. Estimates